PLX-8394 OR PLX-7904 FOR USE IN THE TREATMENT OF BRAF-V600-RELATED DISEASES

摘要

The present disclosure provides methods of treating a subject suffering from or at risk of a BRAF V600 mutation or BRAF fusion mutation related disease or condition, without activating the MAPK pathway or inducing expression of MAPK pathway genes in cells harboring wild-type BRAF.